Transarterial and transvenous access for neurointerventional surgery: Report of the SNIS Standards and Guidelines Committee

Robert M. Starke; Brian Snelling; Fawaz Al-Mufti; Chirag D. Gandhi; Seon Kyu Lee; Guilherme Dabus; Justin F. Fraser

doi:10.1136/neurintsurg-2019-015573

Transarterial and transvenous access for neurointerventional surgery: Report of the SNIS Standards and Guidelines Committee

Robert M. Starke, Brian Snelling, Fawaz Al-Mufti, Chirag D. Gandhi, Seon Kyu Lee, Guilherme Dabus, Justin F. Fraser

Research output: Contribution to journal › Article › peer-review

22 Citations (SciVal)

Abstract

The purpose of this publication is to provide a comprehensive review on the techniques and tools used for vascular access in neurointerventional procedures. Using published literature, we reviewed data on access methods, sites, tools, and techniques for neurointerventions. Recommendations are provided based on quality of data/levels of evidence and, where appropriate, expert consensus. While tools and techniques continue to be developed, current literature and experience supports certain principles regarding vascular access for neurointerventional procedures.

Original language	English
Pages (from-to)	733-741
Number of pages	9
Journal	Journal of NeuroInterventional Surgery
Volume	12
Issue number	8
DOIs	https://doi.org/10.1136/neurintsurg-2019-015573
State	Published - Aug 1 2020

Bibliographical note

Funding Information:
Competing interests JFF is an equity interest holder for Cerelux, and for Fawkes Biotechnology, LLC, and a consultant for Stream Biomedical, Penumbra, and Medtronic Neurovascular. He has research support from the University of Kentucky and the American Heart Association. RMS receives research support from NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, NIH, Miami Clinical and Translational Science Institute, National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. He is a consultant for Penumbra, Abbott, Medtronic, and Cerenovus. GD is a consultant for Medtronic, Microvention, Penumbra, and Cerenovus. He is a shareholder in InNeuroCo, RIST, Cleerly, and eLum. BS has equity in RIST Neurovascular. Dr Kan is a consultant for Stryker and Medtronic Neurovascular. YK is a consultant for Penumbra and for Medtronic Neurovascular. PMM is a consultant for Stryker, Medtronic, Penumbra, and Siemens. ASA is a consultant for Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, and Stryker. He has research support from Cerenovus, Microvention, Penumbra and Siemens. He is a shareholder in Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical, and Vascular Simulations. BB is a consultant for Penumbra, Medtronic, Stryker, Metactive, and 880 Medical, He has stock in Penumbra, and stock options in Viz.ai. He has ownership interest in Route 92 and Marblehead. MC is a consultant for Medtronic, Stryker, Genentech, Imperative Health, Microvention, and Cerenovus. RDL is a consultant for Imperative Care, Siemens, and Penumbra, and owns equity in Q’Apel. He is also on the scientific advisory boards for Cerenovus and receives research support from Asahi and Medtronic. KF is a consultant for Cerebrotech. DF is a consultant for Genentech, Penumbra, and Stryker. He has stock ownership in Penumbra. SH has a Royalty Agreement with Penumbra. He Contracts for Core Imaging Lab for Stryker and MicroVention. He has a research contract with Siemens. He is on Data Safety and Monitoring Boards for DAWN, ARISE2, and PHIL trials. He has grant support through NCI and NIBIB. MSH is a consultant for Cerenovus. MVJ is a speaker for Medtronic. RPK is a consultant for Medtronic, Cerenovus, and Microvention. WJM is a consultant for Q’Apel, Rebound Therapeutics, Viseon TSP, Medtronic, Penumbra, and Stream Biomedical. He is an investor in Cerebrotech, Endostream, Viseon, and Rebound Therapeutics.JMM is a consultant for Stryker and Penumbra. MM is a consultant for Canon Medical and Medtronic. He has financial interest in Serenity Medical and VICIS. JM receives research support from Stryker, Penumbra, Medtronic, and Microvention. He is a consultant for Imperative Care, Cerebrotech, Viseon, Endostream, Rebound Therapeutics, and Vastrax. He is an investor/shareholder in BlinkTBI, Serenity, NTI, Neurvana, and Cardinal Consulting. GLP is a consultant for Sequent and Microvention-Terumo. He is on the Data Safety and Monitoring Board for Web-IT Study (Cerenovus) and for the Pulserider NAPA trial. ATR is a consultant for Stryker Neurovascular and Microventions. He is on an Advisory Board for Cerenovus, and is a stockholder in NTI. CS has equity in Neurotechnology Investors. AHS receives research support from NIH. He has financial interests in Amnis Therapeutics, BlinkTBI, Buffalo Technology Partners, Cardinal Consultants, Cerebrotech Medical Systems, Cognition Medical, Endostream Medical, Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics, Q’Apel Medical, Rebound Therapeutics, Rist Neurovascular, Serenity Medical, Silk Road Medical, Spinnaker Medical, StimMed, Synchron, Three Rivers Medical, and Viseon Spine. He is a consultant for Amnis Therapeutics, Boston Scientific, Canon Medical Systems, Cerebrotech Medical Systems, Cerenovus, Corindus, Endostream Medical, Guidepoint Global Consulting, Imperative Care, Integra, Medtronic, MicroVention, Northwest University, Penumbra, Q’Apel Medical, Silk Road Medical, StimMed, Stryker, Three Rivers Medical, VasSol, and WL Gore and Associates. Dr Toth is a consultant for Dynamed EBSCO.

Publisher Copyright:
©

Keywords

Angiography
Standards
Stroke

ASJC Scopus subject areas

Surgery
Clinical Neurology

Access to Document

10.1136/neurintsurg-2019-015573

Cite this

@article{74282b45d43148239365840f0667a868,

title = "Transarterial and transvenous access for neurointerventional surgery: Report of the SNIS Standards and Guidelines Committee",

abstract = "The purpose of this publication is to provide a comprehensive review on the techniques and tools used for vascular access in neurointerventional procedures. Using published literature, we reviewed data on access methods, sites, tools, and techniques for neurointerventions. Recommendations are provided based on quality of data/levels of evidence and, where appropriate, expert consensus. While tools and techniques continue to be developed, current literature and experience supports certain principles regarding vascular access for neurointerventional procedures.",

keywords = "Angiography, Standards, Stroke",

author = "Starke, {Robert M.} and Brian Snelling and Fawaz Al-Mufti and Gandhi, {Chirag D.} and Lee, {Seon Kyu} and Guilherme Dabus and Fraser, {Justin F.}",

note = "Funding Information: Competing interests JFF is an equity interest holder for Cerelux, and for Fawkes Biotechnology, LLC, and a consultant for Stream Biomedical, Penumbra, and Medtronic Neurovascular. He has research support from the University of Kentucky and the American Heart Association. RMS receives research support from NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, NIH, Miami Clinical and Translational Science Institute, National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. He is a consultant for Penumbra, Abbott, Medtronic, and Cerenovus. GD is a consultant for Medtronic, Microvention, Penumbra, and Cerenovus. He is a shareholder in InNeuroCo, RIST, Cleerly, and eLum. BS has equity in RIST Neurovascular. Dr Kan is a consultant for Stryker and Medtronic Neurovascular. YK is a consultant for Penumbra and for Medtronic Neurovascular. PMM is a consultant for Stryker, Medtronic, Penumbra, and Siemens. ASA is a consultant for Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, and Stryker. He has research support from Cerenovus, Microvention, Penumbra and Siemens. He is a shareholder in Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical, and Vascular Simulations. BB is a consultant for Penumbra, Medtronic, Stryker, Metactive, and 880 Medical, He has stock in Penumbra, and stock options in Viz.ai. He has ownership interest in Route 92 and Marblehead. MC is a consultant for Medtronic, Stryker, Genentech, Imperative Health, Microvention, and Cerenovus. RDL is a consultant for Imperative Care, Siemens, and Penumbra, and owns equity in Q{\textquoteright}Apel. He is also on the scientific advisory boards for Cerenovus and receives research support from Asahi and Medtronic. KF is a consultant for Cerebrotech. DF is a consultant for Genentech, Penumbra, and Stryker. He has stock ownership in Penumbra. SH has a Royalty Agreement with Penumbra. He Contracts for Core Imaging Lab for Stryker and MicroVention. He has a research contract with Siemens. He is on Data Safety and Monitoring Boards for DAWN, ARISE2, and PHIL trials. He has grant support through NCI and NIBIB. MSH is a consultant for Cerenovus. MVJ is a speaker for Medtronic. RPK is a consultant for Medtronic, Cerenovus, and Microvention. WJM is a consultant for Q{\textquoteright}Apel, Rebound Therapeutics, Viseon TSP, Medtronic, Penumbra, and Stream Biomedical. He is an investor in Cerebrotech, Endostream, Viseon, and Rebound Therapeutics.JMM is a consultant for Stryker and Penumbra. MM is a consultant for Canon Medical and Medtronic. He has financial interest in Serenity Medical and VICIS. JM receives research support from Stryker, Penumbra, Medtronic, and Microvention. He is a consultant for Imperative Care, Cerebrotech, Viseon, Endostream, Rebound Therapeutics, and Vastrax. He is an investor/shareholder in BlinkTBI, Serenity, NTI, Neurvana, and Cardinal Consulting. GLP is a consultant for Sequent and Microvention-Terumo. He is on the Data Safety and Monitoring Board for Web-IT Study (Cerenovus) and for the Pulserider NAPA trial. ATR is a consultant for Stryker Neurovascular and Microventions. He is on an Advisory Board for Cerenovus, and is a stockholder in NTI. CS has equity in Neurotechnology Investors. AHS receives research support from NIH. He has financial interests in Amnis Therapeutics, BlinkTBI, Buffalo Technology Partners, Cardinal Consultants, Cerebrotech Medical Systems, Cognition Medical, Endostream Medical, Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics, Q{\textquoteright}Apel Medical, Rebound Therapeutics, Rist Neurovascular, Serenity Medical, Silk Road Medical, Spinnaker Medical, StimMed, Synchron, Three Rivers Medical, and Viseon Spine. He is a consultant for Amnis Therapeutics, Boston Scientific, Canon Medical Systems, Cerebrotech Medical Systems, Cerenovus, Corindus, Endostream Medical, Guidepoint Global Consulting, Imperative Care, Integra, Medtronic, MicroVention, Northwest University, Penumbra, Q{\textquoteright}Apel Medical, Silk Road Medical, StimMed, Stryker, Three Rivers Medical, VasSol, and WL Gore and Associates. Dr Toth is a consultant for Dynamed EBSCO. Publisher Copyright: {\textcopyright} ",

year = "2020",

month = aug,

day = "1",

doi = "10.1136/neurintsurg-2019-015573",

language = "English",

volume = "12",

pages = "733--741",

number = "8",

}

TY - JOUR

T1 - Transarterial and transvenous access for neurointerventional surgery

T2 - Report of the SNIS Standards and Guidelines Committee

AU - Starke, Robert M.

AU - Snelling, Brian

AU - Al-Mufti, Fawaz

AU - Gandhi, Chirag D.

AU - Lee, Seon Kyu

AU - Dabus, Guilherme

AU - Fraser, Justin F.

N1 - Funding Information: Competing interests JFF is an equity interest holder for Cerelux, and for Fawkes Biotechnology, LLC, and a consultant for Stream Biomedical, Penumbra, and Medtronic Neurovascular. He has research support from the University of Kentucky and the American Heart Association. RMS receives research support from NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, NIH, Miami Clinical and Translational Science Institute, National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. He is a consultant for Penumbra, Abbott, Medtronic, and Cerenovus. GD is a consultant for Medtronic, Microvention, Penumbra, and Cerenovus. He is a shareholder in InNeuroCo, RIST, Cleerly, and eLum. BS has equity in RIST Neurovascular. Dr Kan is a consultant for Stryker and Medtronic Neurovascular. YK is a consultant for Penumbra and for Medtronic Neurovascular. PMM is a consultant for Stryker, Medtronic, Penumbra, and Siemens. ASA is a consultant for Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, and Stryker. He has research support from Cerenovus, Microvention, Penumbra and Siemens. He is a shareholder in Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical, and Vascular Simulations. BB is a consultant for Penumbra, Medtronic, Stryker, Metactive, and 880 Medical, He has stock in Penumbra, and stock options in Viz.ai. He has ownership interest in Route 92 and Marblehead. MC is a consultant for Medtronic, Stryker, Genentech, Imperative Health, Microvention, and Cerenovus. RDL is a consultant for Imperative Care, Siemens, and Penumbra, and owns equity in Q’Apel. He is also on the scientific advisory boards for Cerenovus and receives research support from Asahi and Medtronic. KF is a consultant for Cerebrotech. DF is a consultant for Genentech, Penumbra, and Stryker. He has stock ownership in Penumbra. SH has a Royalty Agreement with Penumbra. He Contracts for Core Imaging Lab for Stryker and MicroVention. He has a research contract with Siemens. He is on Data Safety and Monitoring Boards for DAWN, ARISE2, and PHIL trials. He has grant support through NCI and NIBIB. MSH is a consultant for Cerenovus. MVJ is a speaker for Medtronic. RPK is a consultant for Medtronic, Cerenovus, and Microvention. WJM is a consultant for Q’Apel, Rebound Therapeutics, Viseon TSP, Medtronic, Penumbra, and Stream Biomedical. He is an investor in Cerebrotech, Endostream, Viseon, and Rebound Therapeutics.JMM is a consultant for Stryker and Penumbra. MM is a consultant for Canon Medical and Medtronic. He has financial interest in Serenity Medical and VICIS. JM receives research support from Stryker, Penumbra, Medtronic, and Microvention. He is a consultant for Imperative Care, Cerebrotech, Viseon, Endostream, Rebound Therapeutics, and Vastrax. He is an investor/shareholder in BlinkTBI, Serenity, NTI, Neurvana, and Cardinal Consulting. GLP is a consultant for Sequent and Microvention-Terumo. He is on the Data Safety and Monitoring Board for Web-IT Study (Cerenovus) and for the Pulserider NAPA trial. ATR is a consultant for Stryker Neurovascular and Microventions. He is on an Advisory Board for Cerenovus, and is a stockholder in NTI. CS has equity in Neurotechnology Investors. AHS receives research support from NIH. He has financial interests in Amnis Therapeutics, BlinkTBI, Buffalo Technology Partners, Cardinal Consultants, Cerebrotech Medical Systems, Cognition Medical, Endostream Medical, Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics, Q’Apel Medical, Rebound Therapeutics, Rist Neurovascular, Serenity Medical, Silk Road Medical, Spinnaker Medical, StimMed, Synchron, Three Rivers Medical, and Viseon Spine. He is a consultant for Amnis Therapeutics, Boston Scientific, Canon Medical Systems, Cerebrotech Medical Systems, Cerenovus, Corindus, Endostream Medical, Guidepoint Global Consulting, Imperative Care, Integra, Medtronic, MicroVention, Northwest University, Penumbra, Q’Apel Medical, Silk Road Medical, StimMed, Stryker, Three Rivers Medical, VasSol, and WL Gore and Associates. Dr Toth is a consultant for Dynamed EBSCO. Publisher Copyright: ©

PY - 2020/8/1

Y1 - 2020/8/1

N2 - The purpose of this publication is to provide a comprehensive review on the techniques and tools used for vascular access in neurointerventional procedures. Using published literature, we reviewed data on access methods, sites, tools, and techniques for neurointerventions. Recommendations are provided based on quality of data/levels of evidence and, where appropriate, expert consensus. While tools and techniques continue to be developed, current literature and experience supports certain principles regarding vascular access for neurointerventional procedures.

AB - The purpose of this publication is to provide a comprehensive review on the techniques and tools used for vascular access in neurointerventional procedures. Using published literature, we reviewed data on access methods, sites, tools, and techniques for neurointerventions. Recommendations are provided based on quality of data/levels of evidence and, where appropriate, expert consensus. While tools and techniques continue to be developed, current literature and experience supports certain principles regarding vascular access for neurointerventional procedures.

KW - Angiography

KW - Standards

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85076454846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076454846&partnerID=8YFLogxK

U2 - 10.1136/neurintsurg-2019-015573

DO - 10.1136/neurintsurg-2019-015573

M3 - Article

C2 - 31818970

AN - SCOPUS:85076454846

VL - 12

SP - 733

EP - 741

IS - 8

ER -

Transarterial and transvenous access for neurointerventional surgery: Report of the SNIS Standards and Guidelines Committee

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this